Haemonetics (HAE) Proxy Filing summary

Executive summary

• Annual meeting scheduled for July 24, 2025, to elect nine directors, approve executive compensation, and ratify Ernst & Young LLP as auditor for fiscal 2026.

• Fiscal 2025 saw strong performance with $1.361B in revenue (4% reported growth), $4.57 adjusted EPS (15.4% increase), and $144.6M free cash flow (23.3% increase).

• Strategic achievements included new product launches, acquisition of Attune Medical, and divestiture of the Whole Blood product line to focus on higher-margin opportunities.

• Shareholder engagement remained high, with outreach to holders of over 53% of shares and direct meetings with those representing 21% of shares.

Voting matters and shareholder proposals

• Shareholders will vote on director elections, executive compensation (say-on-pay), and auditor ratification.

• Board recommends voting FOR all proposals.

• Shareholder proposals for the 2026 meeting must be submitted by February 10, 2026.

Board of directors and corporate governance

• Board consists of nine members, eight of whom are independent; average director age is 68.1 years and average tenure is 7.8 years.

• Board refreshment is promoted through annual evaluations, peer reviews, and a retirement guideline at age 75.

• Committees (Audit, Compensation, Governance and Compliance, Technology) are composed solely of independent directors.

• Shareholder rights include majority voting, right to call special meetings, and no poison pill.